• Nonglycemic benefits with sodium-glucose cotransporter-2 (SGLT‑2) inhibitors – Metabolic benefits, weight/fat loss benefits, cardiovascular (CV) benefits and renal benefits.
• Cardiovascular disease (CVD) mortality in type 2 diabetes mellitus has remained a significant challenge over the years, and targeting vasculo-metabolic axis is key to sustained improvement in health outcomes.
• Personalized medicine approach and guidelines suggest the preferential use of SGLT-2 inhibitors, for compelling reasons of atherosclerotic CVD (ASCVD), heart failure (HF) or chronic kidney disease (CKD), weight loss or lower risk of hypoglycemia. Agents with proven CVD benefit are recommended for patients with ASCVD.
• SGLT-2 inhibitors have demonstrated consistent CV benefits, including reductions in CV death, HF hospitalizations and nephropathy in type 2 diabetes mellitus with CVD.
• Start early with SGLT-2 inhibitors for cardiorenal protection.
• CREDENCE is the first dedicated kidney outcome trial which showed 30% reduction in primary outcomes like end-stage kidney disease, doubling of serum creatinine or renal or CV death with SGLT-2 inhibitor therapy.

Optimize clinical considerations of risk-benefit for each antidiabetic agent, in principle of individualized approach for every patient.